Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs Ritalin vs fluoxetine in children with ADHD and anxiety
IRCT20211004052670N2Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of atomoxetine, methylphenidate and fluoxetine in attention deficit hyperactivity disorder (ADHD) and anxiety disorder (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Change in anxiety symptoms, Change in ADHD severity and 1 more. Started Feb 2022; status: completed.
02
Drugs
atomoxetinemethylphenidatefluoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)anxiety disorder
Beyond the preview
Go deeper on IRCT20211004052670N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211004052670N2.